Atossa Genetics Inc. (NASDAQ:ATOS) Receives $95.00 Consensus PT from Analysts

Atossa Genetics Inc. (NASDAQ:ATOS) has earned an average rating of “Hold” from the five analysts that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a sell rating, two have assigned a buy rating and one has given a strong buy rating to the company. The average 1 year price target among brokers that have issued ratings on the stock in the last year is $95.00.

A number of brokerages recently issued reports on ATOS. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Atossa Genetics in a research report on Wednesday, January 21st. Ascendiant Capital Markets raised their price target on shares of Atossa Genetics from $116.25 to $120.00 and gave the stock a “buy” rating in a research report on Monday, December 8th.

Hedge Funds Weigh In On Atossa Genetics

Several large investors have recently added to or reduced their stakes in the company. Y Intercept Hong Kong Ltd bought a new stake in shares of Atossa Genetics during the second quarter valued at approximately $321,000. Vanguard Group Inc. boosted its stake in Atossa Genetics by 4.2% during the third quarter. Vanguard Group Inc. now owns 6,078,844 shares of the company’s stock worth $5,270,000 after buying an additional 245,717 shares in the last quarter. Ameriprise Financial Inc. bought a new stake in Atossa Genetics in the 2nd quarter valued at $2,468,000. Squarepoint Ops LLC raised its stake in shares of Atossa Genetics by 39.9% in the 3rd quarter. Squarepoint Ops LLC now owns 253,343 shares of the company’s stock valued at $220,000 after buying an additional 72,235 shares in the last quarter. Finally, Bank of America Corp DE raised its stake in shares of Atossa Genetics by 55.7% in the 2nd quarter. Bank of America Corp DE now owns 99,601 shares of the company’s stock valued at $83,000 after buying an additional 35,629 shares in the last quarter. Institutional investors and hedge funds own 12.74% of the company’s stock.

Atossa Genetics Stock Performance

Atossa Genetics stock opened at $4.21 on Tuesday. Atossa Genetics has a 52 week low of $3.76 and a 52 week high of $19.35. The firm has a market capitalization of $36.25 million, a PE ratio of -1.17 and a beta of 1.36. The business’s 50-day simple moving average is $8.21 and its 200-day simple moving average is $11.10.

Atossa Genetics Company Profile

Atossa Genetics, Inc is a clinical-stage biotechnology company based in Seattle, Washington, focused on developing therapeutics and diagnostic products for breast cancer and other breast-related conditions. The company’s mission centers on delivering targeted, minimally invasive solutions that address early detection, treatment, and prevention in women at risk for or diagnosed with breast malignancies.

The company’s pipeline includes Z-Endoxifen, an oral formulation of endoxifen designed to treat and prevent estrogen receptor–positive breast cancers, particularly in patients with ductal carcinoma in situ or those at high risk of recurrence.